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Abstract
We examine study designs for extending (generalizing or transporting) causal inferences
from a randomized trial to a target population. Specifically, we consider nested trial
designs, where randomized individuals are nested within a sample from the target
population, and non-nested trial designs, including composite dataset designs, where
a randomized trial is combined with a separately obtained sample of non-randomized
individuals from the target population. We show that the causal quantities that can
be identified in each study design depend on what is known about the probability of
sampling non-randomized individuals. For each study design, we examine identification
of potential outcome means via the g-formula and inverse probability weighting. Last,
we explore the implications of the sampling properties underlying the designs for the
identification and estimation of the probability of trial participation.
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A number of recent contributions [1–7] have discussed methods for addressing problems
related to selective study participation [8] in randomized trials. These methods can be
used to extend (i.e., generalize or transport [9]) causal inferences from a randomized
trial to a target population. The methods require baseline covariate, treatment, and
outcome data from individuals participating in the trial and baseline covariate data
from non-randomized individuals. Estimation of potential outcome means in the tar-
get population typically requires models for the probability of trial participation [1],
the expectation of the outcome under each treatment among trial participants [5], or
both (to improve robustness [3, 7]). Prior work has largely focused on identifiability
conditions and estimation approaches, without a clear connection to study design prin-
ciples, obscuring the fact that different study designs determine which causal quantities
can be identified and have implications for identifying and estimating the conditional
probability of trial participation.
Two types of study designs that combine data from randomized individuals with
data from a sample of non-randomized individuals have been used for the explicit goal
of estimating potential outcome means and treatment effects in a well-defined target
population: (1) nested trial designs, in which the randomized trial is embedded in a
sample from the target population [3]; and (2) non-nested trial designs, in which obser-
vations from randomized individuals are combined with a separately obtained sample
of non-randomized individuals from the target population. The sampling probability of
non-randomized individuals is known in nested trial designs [2], but unknown in non-
nested trial designs [4,6,7]. In both types of study designs, baseline covariate data are
collected from all randomized individuals and from sampled non-randomized individu-
als; treatment and outcome data need only be collected from randomized individuals.
Though treatment and outcome data from non-randomized individuals can be used
to evaluate assumptions or improve efficiency, they are not necessary for identification
and estimation under the assumptions used in this paper or the bulk of the related
literature (e.g., as reviewed in [5]).
In this paper, we show that the different causal quantities that can be identified in
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each study design depend on what is known about the probability of sampling non-
randomized individuals. For each study design, we examine identification of potential
outcome means via the g-formula and inverse probability weighting, and explore the
implications of the design’s sampling properties for modeling the probability of trial
participation.
1 Sampling properties and the observed data
For a well-defined causal question, investigators can specify a set of eligibility criteria
that define an actual population of individuals to whom research findings would be
applicable, in the sense that we can in principle identify all individuals who meet the
criteria. For instance, when designing a randomized trial, the trial eligibility criteria
define an actual population of all trial-eligible individuals. In this paper, we view
the actual population as a simple random sample from an (infinite) superpopulation
of individuals; we refer to this superpopulation as the target population [10]. We are
interested in causal quantities that pertain to the target population or to its subsets
(e.g., defined by trial participation status).
To introduce some notation, let X = (X1, . . . , Xp) denote a vector of p baseline
covariates; A the treatment assignment indicator; Y the observed outcome; and S
the trial participation indicator, with S = 1 for randomized individuals and S = 0
for non-randomized individuals (individuals who are either not invited to participate
in the trial or who are invited but decline). To capture the notion that some non-
randomized individuals in the actual population (S = 0) may not be sampled, let D
be an indicator for whether an individual in the actual population is sampled and
contributes data to the analyses, with D = 1 for sampled individuals and D = 0 for
non-sampled individuals..
We can now describe the sampling properties that underlie nested and non-nested
study designs. These properties describe how the observed study sample relates to the
actual population; the underlying actual population and (hypothetical) target popu-
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lation are the same. Figure 1 illustrates the conceptual relationships between designs,
their sampling properties, and the observed data.
In the main text of this paper, we consider simple random samples, with known or
unknown sampling probabilities, from the actual population or from the non-randomized
subset of the actual population. As we discuss below, our main results, with minor
modifications, hold when the sampling probability is a known function of auxiliary
baseline covariates rather than a known constant (i.e., when we have random sam-
pling, not simple random sampling). Allowing the sampling probabilities to depend
on auxiliary covariates, however, does not lead to additional insights regarding study
design [11]; for this reason, in the main text, we assume that the sampling probability
does not depend on covariates.
1.1 Nested trial designs
We consider two variants of the nested trials design: when a census of the actual
population is taken and when the non-randomized individuals are sub-sampled.
Census of the actual population: In this variant of the nested trial design, the
individuals contributing data to the analysis are assumed to be a census of the actual
population, that is,
Pr[D = 1|S = 1] = Pr[D = 1|S = 0] = 1,
thus, nested trial designs can be viewed as simple random samples from the superpop-
ulation. In this design, it is common to define the target population implicitly, based
on the actual population in which the trial is nested. For example, in comprehensive
cohort studies [12], investigators nest a trial within a cohort of all individuals who met
the trial’s eligibility criteria and were invited to participate in the trial. They then
define the target population as the population from which cohort members (i.e., the
actual population of trial-eligible individuals invited to participate in the trials) could
have been a simple random sample. Thus, in this design, investigators need to ensure
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that the cohort represents the target population they are interested in; that is, the trial
eligibility criteria need to be broad enough to address the research question and the
individuals invited to participate in the trial (who form the cohort in which the trial
is nested) need to represent the target population of interest.
Sub-sampling of non-randomized individuals: In this variant, we collect data from
all randomized individuals in the actual population but only collect baseline covariate
data from a sub-sample of the non-randomized individuals in the actual population,
with sampling probability that is a known constant. The sampling properties can be
summarized as
Pr[D = 1|S = 1] = 1 and
Pr[D = 1|X,A, Y, S = 0] = Pr[D = 1|S = 0] = c > 0,
where c is a known constant, with 0 < c ≤ 1. Note that the nested trial design with
a census of the actual population can be viewed as a special case of the sub-sampling
design, with c = 1. Using c < 1 is statistically less efficient than using c = 1, but may
improve research economy, for example, if the collection of covariate data among non-
randomized individuals is expensive [11]. Furthermore, as noted, a variant of the nested
trial design with sub-sampling allows the selection of non-randomized individuals to
depend on auxiliary baseline covariates; we show how our results extend to that case
in the Appendix.
1.2 Non-nested trial designs
In non-nested trial designs, data from randomized and non-randomized individuals are
obtained separately. Investigators assume that data from all randomized individuals
can be combined with data from a simple random sample of non-randomized individuals
from the actual population, with sampling probability that was an unknown constant
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(e.g., [4]). The sampling properties can be summarized as
Pr[D = 1|S = 1] = 1 and
Pr[D = 1|X,A, Y, S = 0] = Pr[D = 1|S = 0] = u > 0, where u is an unknown constant.
An example of non-nested trial design is the composite dataset design [4, 7]. Here,
investigators append the data from a randomized trial to data from a convenience
sample of non-randomized individuals, often obtained from routinely collected data
sources (such as claims or electronic medical records databases, or prospective cohort
studies). The assumption, often left unstated, is that the sample of non-randomized
individuals is a simple random sample from the population of non-randomized individ-
uals (or a well-defined subset thereof) to whom the investigators wish to extend the
trial results [4, 7].
1.3 The observed data
In both nested and non-nested designs, we collect data on baseline covariates, treat-
ment, and outcome from randomized individuals; in contrast, as we show in Section 3,
only baseline covariate data are needed from non-randomized individuals.
More specifically, for nested designs the observed data consist of realizations of
(X,A, Y, S = 1, D = 1) for trial participants;
(X,S = 0, D = 1) for sampled non-randomized individuals;
(S = 0, D = 0) for non-sampled non-randomized individuals.
Because all randomized individuals are sampled, we have that (D = 1, S = 1) ⇔
(S = 1). No covariate, treatment, or outcome data are available for non-sampled non-
randomized individuals, (D = 0, S = 0). Note also that in nested trial designs with a
census of the actual population, the (D = 0, S = 0) subset does not exist.
In non-nested trial designs (e.g., composite dataset designs), we typically do not
know the number of non-sampled non-randomized individuals, thus the observed data
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consist of realizations only of
(X,A, Y, S = 1, D = 1) for trial participants; and
(X,S = 0, D = 1) for sampled non-randomized individuals.
2 Causal quantities of interest and identifiabil-
ity conditions
2.1 Causal quantities of interest
In order to define causal quantities, let Y a be the potential (counterfactual) outcome
under intervention to set treatment to a [13,14]. We are interested in the mean of these
potential outcomes in the target population E[Y a] or in the non-randomized subset of
the target population E[Y a|S = 0]. For example, E[Y a] captures the outcome under
the strategy of treating all individuals in the target population with a. And it is
often scientifically and methodologically interesting to compare E[Y a|S = 0] against
E[Y a|S = 1], to examine whether the potential outcome mean under treatment a differs
among trial-participants and non-participants in the target population [3].
2.2 Identifiability conditions
For all study designs, the following identifiability conditions are sufficient to extend
inferences from a clinical trial to a target population [3, 7]:
(1) Consistency of potential outcomes: interventions are well-defined, so that if Ai = a,
then Y ai = Yi. Implicit in this notation is that the offer to participate in the trial and
trial participation itself do not have an effect on the outcome except through treatment
assignment (e.g., there are no Hawthorne effects).
(2) Mean exchangeability among trial participants: E[Y a|X,S = 1, A = a] = E[Y a|X,S =
1]. This condition is expected to hold because of randomization (marginal or condi-
tional on X).
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(3) Positivity of treatment assignment in the trial: Pr[A = a|X = x, S = 1] > 0 for each
a and each x with positive density among randomized individuals, fX|S(x|S = 1) > 0.
This condition is also expected to hold because of randomization.
(4) Mean generalizability (exchangeability over S): E[Y a|X,S = 1] = E[Y a|X] for
each a. For binary S, this condition implies the mean transportability condition
E[Y a|X,S = 1] = E[Y a|X,S = 0] (provided both conditional expectations are well-
defined).
(5) Positivity of trial participation: Pr[S = 1|X = x] > 0 for each x with positive
density in the target population, fX(x) > 0.
In the conditions listed above, we have used X generically to denote baseline covari-
ates. It is possible, however, that strict subsets of X are adequate to satisfy different
exchangeability conditions. For example, in a marginally randomized trial the mean
exchangeability among trial participants holds unconditionally. Furthermore, to focus
on issues related to selective trial participation, we will assume complete adherence to
the assigned treatment and no loss-to-follow-up.
2.3 Trial eligibility criteria and choice of target popula-
tion
Now that we have specified the causal quantities of interest and listed identifiability
conditions, we can consider the choice of target population in more detail. As noted,
the target population should be determined by the scientific question investigators
hope to address. In many cases, when using the methods described in this paper, it is
sensible to limit the target population to the population of individuals meeting the trial
eligibility criteria or to a subset of that population. To the extent that the variables
used to define the trial eligibility criteria are needed to satisfy the mean generalizability
condition, the restriction to trial-eligible individuals is needed for the positivity of trial
participation condition to hold – individuals not meeting the criteria are not allowed
to enter the trial. In some cases, however, investigators may be able to argue that only
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a subset of the variables used to determine trial eligibility are necessary for the mean
generalizability condition to hold. In such cases, the target population can be broader
than the population of trial eligible individuals. The essential requirement is that the
distributions of covariates needed to satisfy the mean generalizability condition among
randomized and non-randomized individuals should have common support.
3 Identification via the g-formula
We begin by considering identification by the g-formula [15]. Using the identifiability
conditions of Section 2, it is straightforward to show that the potential outcome mean
in the target population [3] can be re-expressed as
E[Y a] = E
[
E[Y |X,S = 1, A = a]]
=
∫
E[Y |X = x, S = 1, A = a]dFX(x),
(1)
where FX(x) denotes the distribution of X in the target population.
The potential outcome mean among non-randomized individuals in the target pop-
ulation [7] can be re-expressed as
E[Y a|S = 0] = E[E[Y |X,S = 1, A = a]|S = 0]
=
∫
E[Y |X = x, S = 1, A = a]dFX|S(x|S = 0),
(2)
where FX|S(x|S = 0) denotes the distribution of X among non-randomized individuals
in the target population (i.e., the subset with S = 0).
First, we note that both results involve the conditional expectation of the outcome Y
among trial participants assigned to treatment a, E[Y |X,A = a, S = 1]. Because both
nested and non-nested designs assume that all randomized individuals are sampled,
this expectation is identifiable in both designs.
Next, we turn out attention to the identification of FX(x) and FX|S(x|S = 0), which
are necessary to identify E[Y a] and E[Y a|S = 0], respectively. There are interesting
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differences between the designs when it comes to identifying these distributions and we
consider each design individually below.
3.1 Nested trial designs
Census of the actual population: Identification is most straightforward in this design,
because data are available from all members of the actual population (both randomized
and non-randomized) and the actual population is a simple random sample from the
target population. Thus, FX(x) is identifiable. Furthermore, in this design, every
subgroup of the actual population defined on the basis of baseline covariates or trial
participation is a simple random sample from the corresponding subgroup in the target
population. Thus, the distribution of covariates among non-randomized individuals
FX|S(x|S = 0) can also be identified. It follows that all the components on the right-
hand-sides of (1) and (2) are identifiable, establishing that E
[
E[Y |X,S = 1, A = a]]
and E
[
E[Y |X,S = 1, A = a]∣∣S = 0] are identifiable.
Sub-sampling of non-randomized individuals: For this design, identification of the
marginal distribution of X is slightly more involved because the non-randomized indi-
viduals contributing data to the analysis are a sub-sample from the non-randomized
individuals in the actual population.
First, by the law of total probability, for binary S,
FX(x) =
1∑
s=0
FX|S(x|S = s) Pr[S = s].
Clearly, FX|S(x|S = s), for s = 0, 1 is identifiable because the randomized and non-
randomized sampled individuals are simple random samples of the target population
subsets with S = 1 and S = 0, respectively. The only difficulty, then, is identification
of the marginal probability of trial participation, Pr[S = 1], because Pr[S = 0] =
1 − Pr[S = 1]. As we show in the Appendix, under the sampling properties of the
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nested trial design with sub-sampling of non-randomized individuals,
Pr[S = 1] =
{
1 +
Pr[S = 0|D = 1]
Pr[S = 1|D = 1] × c
−1
}−1
. (3)
The odds of non-participation in the trial among sampled individuals,
Pr[S = 0|D = 1]
Pr[S = 1|D = 1],
are identifiable; and, as defined in Section 1.1, c is a known constant. It follows that
FX(x) is identifiable and, consequently, E
[
E[Y |X,S = 1, A = a]] is also identifiable
because all the components of the integral on the right-hand-side of (1) are identifiable.
Turning our attention to FX|S(x|S = 0), we note that it is identifiable because
the sampled non-randomized individuals are a simple random sample from the non-
randomized individuals in the actual population. It follows that E
[
E[Y |X,S = 1, A =
a]|S = 0] is identifiable because all the components of the integral on the right-hand-
side of (2) are identifiable.
3.2 Non-nested trial designs
Using an argument parallel to that for nested trial designs with sub-sampling, when
the probability of sampling a non-randomized individual is unknown, the probability of
trial participation, Pr[S = 1], can be expressed in the form of equation (3), substituting
the u for c,
Pr[S = 1] =
{
1 +
Pr[S = 0|D = 1]
Pr[S = 1|D = 1] × u
−1
}−1
.
Because, as defined in Section 1.2, u is an unknown constant, FX(x) is not identifiable
and consequently E
[
E[Y |X,S = 1, A = a]] is also not identifiable.
Turning our attention to FX|S(x|S = 0), we see that it is identifiable because the
non-randomized individuals contributing data to the analysis are a simple random
sample from the non-randomized individuals in the actual population (even though
the sampling probability is unknown). It follows that E
[
E[Y |X,S = 1, A = a]∣∣S = 0]
is identifiable in non-nested trial designs because all the components of the integral in
(2) are identifiable.
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4 Identification via IP weighting
There has been considerable recent interest [1–4, 7] in using weighting methods to
identify the potential outcome means in equations (1) and (2), because the specification
of models for the probability of trial participation is often considered a somewhat easier
task than the specification of models for the outcome among trial participants.
First, consider E
[
E[Y |X,S = 1, A = a]], which we argued is identifiable in nested
trials. As shown in [3], we can re-express the right-hand-side of (1) as
E
[
E[Y |X,S = 1, A = a]] = E[ I(S = 1, A = a)Y
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
, (4)
where I(·) denotes the indicator function.
Now, consider E
[
E[Y |X,S = 1, A = a]|S = 0], which we argued is identifiable by
the g-formula in both nested and non-nested trials. As shown in [7], we can re-express
the right-hand-side of (2) as
E
[
E[Y |X,S = 1, A = a]∣∣S = 0] = E
[
I(S = 1, A = a)Y Pr[S = 0|X]
Pr[S = 1|X] Pr[A = a|X,S = 1]
]
E
[
I(S = 1, A = a) Pr[S = 0|X]
Pr[S = 1|X] Pr[A = a|X,S = 1]
] . (5)
The probability of treatment among trial participants, Pr[A = a|X,S = 1] is under
the control of the investigators and does not pose any difficulties for identification of
either functional. Now, for each design, we focus our attention on the conditional
probability or the conditional odds of trial participation, which appear in expressions
(4) and (5), respectively.
4.1 Nested trial designs
Census of the actual population: Identification of Pr[S = 1|X] in this design is an
obvious consequence of the fact that individuals contributing data to the analysis are
a simple random sample from the target population. In other words, because we have
sampled all individuals in the actual population, which is a simple random sample of
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the target population, Pr[S = 1|X] = Pr[S = 1|X,D = 1].
Sub-sampling of non-randomized individuals: Identification of Pr[S = 1|X] is only
a little more difficult when we sample non-randomized individuals from the actual
population. As we show in the Appendix, under the sampling properties of this design,
Pr[S = 1|X] =
{
1 +
Pr[S = 0|X,D = 1]
Pr[S = 1|X,D = 1] × c
−1
}−1
, (6)
where the conditional odds of trial participation among sampled individuals,
Pr[S = 0|X,D = 1]
Pr[S = 1|X,D = 1],
are identifiable and c is a known constant defined in Section 1.1. It follows that
Pr[S = 1|X] is identifiable and the odds of trial participation can be written as
Pr[S = 1|X]
Pr[S = 0|X] =
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] × c. (7)
In sum, the IP weighting re-expressions of the functionals of interest are identifiable in
nested trial designs.
4.2 Non-nested trial designs
We can use an argument parallel to that for nested trial designs with sub-sampling,
to establish that, when the sampling probability for non-randomized individuals is
unknown, the probability of trial participation, Pr[S = 1|X], can be expressed as,
Pr[S = 1|X] =
{
1 +
Pr[S = 0|X,D = 1]
Pr[S = 1|X,S = 1] × u
−1
}−1
. (8)
Because, as defined in Section 1.2, u is unknown, the conditional probability of trial
participation, which appears on the right hand side of (4), is not identifiable; this
confirms our earlier result that E
[
E[Y |X,S = 1, A = a]] cannot be identified in non-
nested trials.
Furthermore, the conditional odds of trial participation are also not identifiable be-
cause they depend on u. In fact, using equation (7), substituting u for c, we see that the
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odds of trial participation in the target population are, up to an unknown multiplicative
constant, equal to the odds of trial participation among sampled individuals,
Pr[S = 1|X]
Pr[S = 0|X] =
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] × u. (9)
We have come to an apparent conflict: the right hand-side of (5) involves the con-
ditional odds of trial participation, a quantity that is not identifiable in non-nested
designs. Yet, we argued in the previous section that the left-hand-side of (5) is identi-
fiable. The conflict can be easily resolved by noting that, because both the numerator
and the denominator of (5) are multiplied by the unknown constant u, which cancels
out, identification via IP weighting is possible (see the appendix of [7] for technical
details).
Table 1 summarizes the sampling properties and identification results for each study
design.
5 Estimating the probability of trial participa-
tion
In realistic analyses, the dimension of X will be fairly large, necessitating some mod-
eling assumptions about Pr[S = 1|X] or Pr[S = 1|X,D = 1] [16]. In this section we
discuss the relationship between study design and model specification and estimation
approaches.
5.1 Nested trial designs
Census of the actual population: In this type of nested trial design, it is straightforward
to estimate the probability of trial participation, Pr[S = 1|X], in the sense that we
can use the model we believe is most likely to be correctly specified for the target
population.
For concreteness, suppose that we are willing to assume a parametric model, p(X; γ),for
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the probability of trial participation in the target population, Pr[S = 1|X], with
γ a finite dimensional parameter. In the nested-trial designs with a census of non-
randomized individuals, we typically estimate the parameters by maximizing the like-
lihood function
L (γ) =
n∏
i=1
[p(Xi; γ)]
Si [1− p(Xi; γ)]1−Si ,
where i = 1, . . . , n, and n is the number of individuals in the study (i.e., the actual
population). Under reasonable technical conditions [17], the usual maximum likelihood
methods use a sample-size normalized objective function that converges uniformly in
probability to
`0(γ) = E
[
S log
[
p(X; γ)
]
+ (1− S) log [1− p(X; γ)]]. (10)
For example, when p(X; γ) is a logistic model, `0(γ) is the large sample limit of the
sample-size normalized log-likelihood function for logistic regression.
Sub-sampling of non-randomized individuals: When we sub-sample of the non-
randomized individuals in the actual population, it is not possible to maximize the
likelihood function above, because data are not available from all non-randomized indi-
viduals in the actual population. A natural idea is to use equation (6), which provides
an explicit formula for identifying the conditional probability of trial participation,
Pr[S = 1|X] using the probability of trial participation among sampled individuals,
Pr[S = 1|X,D = 1], and the sampling probability for non-randomized individuals,
Pr[D = 1|S = 0]. When modeling the probability of trial participation among sampled
individuals, however, the following difficulty arises: in general, when sampling depends
on trial participation status, the correctly specified model for trial participation does
not have the same form as the correctly specified model in the target population,
with the notable exception of the logistic regression model [18, 19]. This implies that
naive estimation of the parameters of the model for trial participation among sampled
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individuals will typically be inconsistent for the population model.
Because the sampling probability of non-randomized individuals is known, we can
use the following weighted pseudo-likelihood function, which only uses data from sam-
pled individuals [18,20],
LW(γ) =
n∏
i=1
[
p(Xi; γ)
]SiDi[1− p(Xi; γ)][(1−Si)Di]/c,
with c = Pr[D = 1|S = 0]. Weighted maximum likelihood methods use a sample-size
normalized objective function that converges uniformly in probability to
`W0(γ) = E
[
SD log
[
p(X; γ)
]
+
[(1− S)D
c
log
[
1− p(X; γ)]] , (11)
which is restricted to sampled individuals (D = 1).
As we show in the Appendix, under the sampling properties for this design, the large
sample limits of the objective functions in (10) and (11) are equal, `0(γ) = `W0(γ). It
follows that, under reasonable technical conditions [17], weighted likelihood estima-
tion of γ in the nested trial design with sub-sampling of non-randomized individuals
converges in probability to the same parameter as unweighted regression in the actual
population.
In practical terms, as long as a reasonable parametric model can be specified for the
target population, the model parameters can be estimated using weighted maximum
likelihood methods [18] on data from sampled individuals, with individual level weights
equal to 1 for randomized individuals, S = 1, D = 1; c−1 for sampled non-randomized
individuals, S = 0, D = 1; and 0 for unsampled individuals, D = 0.
5.2 Non-nested trial designs
In non-nested trial designs, the weighting approach described above is not applicable
because the sampling probability of non-randomized individuals is unknown. Provided,
however, that the sampling probability does not depend on X (i.e., the assumed sam-
16
pling property), we can show that, if a logistic model for trial participation is correctly
specified in the target population, then a logistic model is correctly specified in the
non-nested trial design. To see this, suppose that we are willing to assume a logistic
regression model in the population, such that
ln
Pr[S = 1|X]
Pr[S = 0|X] = β0 +
p∑
j=1
βjXj .
Using the result in (8) and taking logarithms, we have that
ln
Pr[S = 1|X]
Pr[S = 0|X] = ln(u) + ln
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] .
Equating the right-hand-sides of the last two equations, we obtain
ln
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] = β
∗
0 +
p∑
j=1
βjXj , (12)
where β∗0 = β0 − ln(u), a well-known result in the context of case-referent studies [21].
Thus, if a logistic model is correctly specified in the target population, then a model of
the same functional form is correctly specified in the non-nested trial design. In fact,
the coefficients in the two models are equal, and only the intercept differs. Because
0 < u < 1, β∗0 > β0: the sub-sampling of non-randomized patients simply results in an
intercept that is “shifted” upwards. As we have shown in the section on IP weighting,
the resulting shift in the odds of participation does not affect identification of the
potential outcome mean in the non-randomized individuals, E[Y a|S = 0], which is the
parameter of interest in non-nested trial designs with unknown sampling probability
of non-randomized individuals.
The above result is also important for estimation of the model parameters: com-
bined with the results in [22, 23], it implies that the unconstrained and unweighted
maximum likelihood estimator for the logistic model in (12), fit among sampled indi-
viduals, is the efficient estimator for βj , j = 1, . . . , p.
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6 Discussion
We presented a unified description of study designs for extending inferences from ran-
domized trials to a well-defined target population and showed that commonly invoked
identifiability conditions need to be combined with the sampling properties of each
study design in order to determine which causal quantities can be identified. Our ap-
proach uses a superpopulation framework, which is a natural choice for extending trial
findings beyond the sample of randomized individuals [24].
In non-nested trial designs, where the sampling probability for non-randomized in-
dividuals is unknown, the marginal potential outcome means in the target population
are not identifiable, but the potential outcome means in the sub-population of non-
randomized individuals are identifiable. This restriction may be less severe than it
appears: for most trials, we want to estimate the effect of applying the interventions to
a new population, which can be represented by a well-chosen sample of non-randomized
individuals [7]. In any case, when available, knowledge of the sampling probability of
non-randomized individuals can be used to mitigate these limitations, without requir-
ing the collection of covariate information from all non-randomized individuals in the
actual population. Thus, in general, nested trial designs will often be the preferred ap-
proach for generalizing trial findings when it is possible to define and sample the actual
population when a randomized trial is planned. Such nested trial designs will typically
have broad (pragmatic [25]) eligibility criteria and define the target population as the
population of individuals meeting the trial eligibility criteria. When that is not pos-
sible, as is the case in already completed randomized trials, non-nested trial designs
might be a reasonable alternative. For example, in non-nested trial designs, the com-
parison of estimates for the potential outcome means among randomized, Ê[Y a|S = 1],
and non-randomized individuals, Ê[Y a|S = 0], is of practical interest: provided the
identifiability conditions hold, if Ê[Y a|S = 1] ≈ Ê[Y a|S = 0], we may conclude that
the trial results are likely generalizable (up to sampling variability); in contrast, if the
estimates are different, trial results may not be generalizable.
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We also showed that the different study designs have implications for identify-
ing and estimating the conditional probability of trial participation. This probability
is of inherent interest because it captures aspects of decision-making related to trial
participation [26, 27]. We showed that the probability is identifiable in nested trial
designs, but not in non-nested trial designs (e.g., composite dataset designs). Indeed,
any reasonable parametric model for the probability of participation in the popula-
tion can be identified in nested trial designs. In nested trial designs with sampling of
non-randomized individuals, estimation of model parameters can be facilitated by the
use of weighted maximum likelihood estimation where randomized patients are given
weight 1 and non-randomized patients are given weight equal to the inverse of the prob-
ability of being sampled among non-randomized individuals in the actual population.
In non-nested trial designs, model specification is complicated by the fact that, when
sampling depends on trial participation status, the model for the probability of trial
participation among sampled individuals is not of the same form as the model in the
population (the logistic regression model being a notable exception [18]).
The probability of trial participation in the target population is also important for
identification and estimation using inverse probability (or odds) weighting methods.
Our argument about the odds of participation after selection of non-randomized in-
dividuals being equal to the odds of participation in the target population up to an
unknown multiplicative constant, clarifies how the validity of estimators when using
composite datasets designs [4,7] depends critically on the assumed sampling properties.
Astute readers will have noticed the many connections between our results and
the theory of case-referent (case-control) studies [18–21,28]. Indeed, our approach can
be placed in the case-base paradigm, viewing randomized individuals as “cases” in
cumulative incidence case-referent study [28] nested in the “cohort” of the actual pop-
ulation. An interesting parallel with case-referent studies: the difficulty in specifying
the population of non-randomized individuals that should be sampled in composite
dataset designs is similar in nature to the validity issues of case-referent studies with
a secondary base [29–31].
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In this paper, for simplicity, we focused on causal quantities that are most meaning-
ful for point treatments with complete adherence and no loss to follow-up. Our results
can be extended to address time-varying treatments using well-known extensions of the
identifiability conditions for randomized trials [15, 24, 32], without any changes to the
sampling properties or the modeling assumptions about the probability of trial par-
ticipation. Perhaps, then, the most consequential causal assumption that we required
was that the invitation to participate in the trial and trial participation itself do not
have an effect on the outcome except through treatment assignment. Unless investiga-
tors are willing to contemplate much more complex study designs involving multistage
data collection about (and possibly randomization of) the invitation to participate,
trial participation itself, and treatment assignment [33], our results are best viewed
as applying to trials where the not-through-treatment effects of the invitation to par-
ticipate in the trial and of trial participation are negligible compared to the effects of
treatment. For example, they are applicable to pragmatic randomized trials embedded
in large health-care systems or registries, where trial procedures other than treatment
assignment can be assumed to be similar to usual medical practice [25,34,35].
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7 Figure
Figure 1: Conceptual graph depicting the sampling designs for studies extending inferences
from a randomized trial to a target population.
S = 1 S = 0
Study sampleS = 1, D = 1 D = 0S = 0, D = 1
Pr[D = 1|S = 1] Pr[D = 1|S = 0]
Target population
(superpopulation)
Actual population
Actual population after trial 
participation status is determined
Pr[S = 1|X] Pr[S = 0|X]
Simple random sampling
Participation in the trial
Selection into the data
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Appendix A Identification of the probability of
trial participation in nested trial designs with
sub-sampling
A.1 Identification of the marginal probability of trial par-
ticipation
Using the definition of conditional probability and re-arranging,
Pr[S = 1] =
Pr[S = 1|D = 1] Pr[D = 1]
Pr[D = 1|S = 1] and Pr[S = 0] =
Pr[S = 0|D = 1] Pr[D = 1]
Pr[D = 1|S = 0] .
Taking the ratio of the above expressions and exploiting the sampling properties for
non-nested trial designs,
Pr[S = 1]
Pr[S = 0]
=
Pr[S = 1|D = 1]
Pr[S = 0|D = 1] ×
Pr[D = 1|S = 0]
Pr[D = 1|S = 1]
=
Pr[S = 1|D = 1]
Pr[S = 0|D = 1] × c.
With a bit of algebra, the above expression can be re-arranged to show that
Pr[S = 1] =
{
1 +
Pr[S = 0|D = 1]
Pr[S = 1|D = 1] × c
−1
}−1
.
By setting c = 1 we see that in the nested-trial design with a census of non-
randomized individuals Pr[S = 1] = Pr[S = 1|D = 1].
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A.2 Identification of the conditional probability of trial
participation
The argument for the conditional probability is parallel to the one presented above for
the marginal probability. Again, using the definition of conditional probability,
Pr[S = 1|X] = Pr[S = 1|X,D = 1] Pr[D = 1|X]
Pr[D = 1|X,S = 1] and
Pr[S = 0|X] = Pr[S = 0|X,D = 1] Pr[D = 1|X]
Pr[D = 1|X,S = 0] .
Taking the ratio of the above expressions and exploiting the sampling properties for
non-nested trial designs,
Pr[S = 1|X]
Pr[S = 0|X] =
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] ×
Pr[D = 1|X,S = 0]
Pr[D = 1|X,S = 1]
=
Pr[S = 1|X,D = 1]
Pr[S = 0|X,D = 1] × c.
The above expression can be re-arranged to show that
Pr[S = 1|X] =
{
1 +
Pr[S = 0|X,D = 1]
Pr[S = 1|X,D = 1] × c
−1
}−1
.
By setting c = 1 we see that in the nested-trial design with a census of non-
randomized individuals Pr[S = 1|X] = Pr[S = 1|X,D = 1].
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Appendix B Estimating the conditional proba-
bility of trial participation
We outline the proof for the convergence in probability of the estimators for the con-
ditional probability of trial participation described in the main text, without delving
into the technical conditions needed to make the arguments rigorous.
Consider the likelihood function for the nested trial design with a census of the
actual population,
L (γ) =
n∏
i=1
[
p(Xi; γ)
]Si[1− p(Xi; γ)]1−Si ,
and, the pseudo-likelihood function for the nested trial design with known sampling
probability of the non-randomized individuals,
LW(γ) =
n∏
i=1
[
p(Xi; γ)
]SiDi[1− p(Xi; γ)][(1−Si)Di]/c.
For L (γ), the sample size-normalized objective function to be maximized is
̂`(γ) = 1
n
n∑
i=1
{
Si log p(Xi; γ) + (1− Si) log
[
1− p(Xi; γ)
]}
.
Provided the technical conditions for the uniform law of large numbers obtain, the
above objective function converges uniformly in probability, in the sense of the defini-
tion in Section 2.1 of [17], to
`0(γ) = E
[
S log p(X; γ) + (1− S) log [1− p(X; γ)]].
By Theorem 2.1 of [17], if `0(γ) is uniquely maximized at γ0, the parameter space is
compact, and `0(γ) is continuous, then the estimator γ̂ obtained by maximizing ̂`(γ),
converges in probability to γ0, that is, γ̂
p−→ γ0.
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For LW(γ), the sample size-normalized objective function to be maximized is
̂`
W(γ) =
1
n
n∑
i=1
{
SiDi log p(Xi; γ) +
(1− Si)Di
c
log
[
1− p(Xi; γ)
]}
.
Because c is assumed to be bounded away from 0, and provided the technical condi-
tions for the uniform weak law of large numbers obtain, the above objective function
converges uniformly in probability to
`W0(γ) = E
[
SD log p(X; γ) +
(1− S)D
c
log
[
1− p(X; γ)]] .
We will now show that `0(γ) = `W0(γ).
By design, if S = 1, then SD = 1; if S = 0, then SD = 0. Thus, to establish the
result we only need to show that
E
[
(1− S) log[1− p(X; γ)] = E [(1− S)D
c
log
[
1− p(X; γ)]] .
Starting from the right-hand-side,
E
[
(1− S)D
c
log
[
1− p(X; γ)]] = E [ log [1− p(X; γ)]∣∣S = 0, D = 1]Pr[S = 0, D = 1]
c
= E
[
log
[
1− p(X; γ)]∣∣S = 0]Pr[S = 0]
= E
[
(1− S) log [1− p(X; γ)]],
which establishes the result.
Because `0(γ) = `W0(γ), it follows that the maximizer of ̂`W(γ), γ̂W, converges in
probability to γ0, that is, γ̂W
p−→ γ0.
To obtain the asymptotic distribution of the estimators, we need additional techni-
cal conditions as in Theorem 3.1 of [17]; provided these conditions hold, γ̂ and γ̂W are
asymptotically normal.
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Appendix C Nested trial design with covariate-
dependent sampling probabilities
C.1 Sampling properties
As noted in the main text, a more general version of the nested trial design assumes that
the sampling probabilities for non-randomized individuals depend on baseline auxiliary
covariates. Let X = (X1, X2), where X1 represents baseline auxiliary covariates that
are available on all members of the actual population in which the trial is nested, and
X2 represents covariates that are only measured among randomized individuals (S = 1)
and sampled non-randomized individuals (S = 1, D = 1).
The identifiability conditions and identification results remain the same as in the
main text; but the sampling properties of this design are
Pr[D = 1|S = 1] = 1, and
Pr[D = 1|X,A, Y, S = 0] = Pr[D = 1|X1, S = 0] ≡ c(X1),
where 0 < c(X1) ≤ 1 is a known function that only depends on X1, allowing the
sampling of non-randomized individuals to depend on the auxiliary covariates that are
available from all members of the actual population.
C.2 Identification of the conditional probability of trial
participation
Using an argument similar to the case when the sampling probability for non-randomized
individuals does not depend on covariates, we obtain
Pr[S = 1|X] =
{
1 +
Pr[S = 0|X,D = 1]
Pr[S = 1|X,D = 1] ×
1
c(X1)
}−1
,
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which is identifiable because the inverse of the conditional odds of trial participation in
the sampled data,
Pr[S = 0|X,D = 1]
Pr[S = 1|X,D = 1], are identifiable, and c(X1) is known, by design.
C.3 Estimating the probability of trial participation by
weighted regression
As before, we assume a model p(X; γ) for Pr[S = 1|X] with finite-dimensional param-
eter γ. The weighted pseudo-likelihood function becomes
L ∗W (γ) =
n∏
i=1
[
p(Xi; γ)
]SiDi[1− p(Xi; γ)][(1−Si)Di]/c(X1i).
Note that the only difference between L ∗W (γ) and LW(γ) is that the weights in the
former depend on X1. The sample size-normalized objective function to be maximized
is ̂`∗
W(γ) =
1
n
n∑
i=1
{
SiDi log p(Xi; γ) +
(1− Si)Di
c(X1i)
log
[
1− p(Xi; γ)
]}
.
Because c(X1) is assumed to be bounded away from 0, and provided the technical
conditions for the uniform weak law of large numbers obtain, the above objective
function converges uniformly in probability to
`∗W0(γ) = E
[
SD log p(X; γ) +
(1− S)D
c(X1)
log
[
1− p(X; γ)]] .
We will now show that `0(γ) = `
∗
W0(γ).
As noted above, by design, if S = 1, then SD = 1; if S = 0, then SD = 0. Thus,
to establish the result we only need to show that
E
[
(1− S) log [1− p(X; γ)]] = E [(1− S)D
c(X1)
log
[
1− p(X; γ)]] .
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Starting from the right-hand-side,
E
[
(1− S)D
c(X1)
log
[
1− p(X; γ)]] = E[E [(1− S)D
c(X1)
log
[
1− p(X; γ)]∣∣∣X1]]
= E
[
1
c(X1)
E
[
(1− S)D log [1− p(X; γ)]∣∣X1] ]
= E
[
Pr[S = 0, D = 1|X1]
c(X1)
E
[
log
[
1− p(X; γ)]∣∣X1, S = 0, D = 1] ]
= E
[
Pr[S = 0|X1] E
[
log
[
1− p(X; γ)]∣∣X1, S = 0, D = 1] ]
= E
[
Pr[S = 0|X1] E
[
log
[
1− p(X; γ)]∣∣X1, S = 0] ]
= E
[
E
[
(1− S) log [1− p(X; γ)]∣∣X1] ]
= E
[
(1− S) log [1− p(X; γ)]],
which establishes the result.
Because `0(γ) = `
∗
W0(γ), it follows that the maximizer of
̂`∗
W(γ), γ̂
∗
W, converges in
probability to γ0, that is, γ̂
∗
W
p−→ γ0.
In practical terms, this result suggests that the conditional probability of trial
participation in the target population can be estimated using a weighted regression
of S on X among sampled patients, using weights equal to 1 for randomized patients
(all of whom are sampled); 1/c(X1) for sampled non-randomized individuals; 0 for
non-sampled non-randomized individuals.
As above, provided the technical conditions of Theorem 3.1 of [17] hold, γ̂∗W is
asymptotically normal.
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